The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications
[Display omitted] Nitric oxide (NO) and hydrogen sulfide (H2S) are industrial toxins or pollutants; however, both are produced endogenously and have important biological roles in most mammalian tissues. The recognition that these gasotransmitters have a role in physiological and pathophysiological p...
Gespeichert in:
| Veröffentlicht in: | Biochemical pharmacology 2020-06, Vol.176, p.113931-113931, Article 113931 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 113931 |
|---|---|
| container_issue | |
| container_start_page | 113931 |
| container_title | Biochemical pharmacology |
| container_volume | 176 |
| creator | Dillon, Kearsley M. Carrazzone, Ryan J. Matson, John B. Kashfi, Khosrow |
| description | [Display omitted]
Nitric oxide (NO) and hydrogen sulfide (H2S) are industrial toxins or pollutants; however, both are produced endogenously and have important biological roles in most mammalian tissues. The recognition that these gasotransmitters have a role in physiological and pathophysiological processes has presented opportunities to harness their intracellular effects either through inhibition of their production; or more commonly, through inducing their levels and or delivering them by various modalities. In this review article, we have focused on an array of NO and H2S donors, their hybrids with other established classes of drugs, and the various engineered delivery platforms such a fibers, polymers, nanoparticles, hydrogels, and others. In each case, we have reviewed the rationale for their development. |
| doi_str_mv | 10.1016/j.bcp.2020.113931 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7263970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006295220301593</els_id><sourcerecordid>S0006295220301593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-6ff1b330e9e1220fb8b440ec71e8b71bd4a26ad7ef3930698de68505d6d607633</originalsourceid><addsrcrecordid>eNp9UV1rGzEQFCWlcdz8gL4E_QE7-jjr7hIIGNOmhUBf0mehk1a2jCwZ6XzJJX--Mk5D-9InaXdnZtkZhL5QMqeEiuvtvNP7OSOs1JS3nH5AE9rUfMZa0ZyhCSFElP-CnaOLnLfHshH0EzrnjLGqMCbo9XEDGIboBxfW2KtgslZ7wDYmrMH7g1cJB9cnp3F8dgZwgeDNaFJcQ8D54O2xacC7AdKI85h72OUbvMQBnjAkhaPF-pD7uHMvYPAOjNOqdzHkz-ijVT7D5ds7Rb--fX1cfZ89_Lz_sVo-zHS1oP1MWEs7zgm0QBkjtmu6qiKgawpNV9POVIoJZWqwxQIi2saAaBZkYYQRpBacT9HdSXd_6Mp6DaFPyst9cjuVRhmVk_9OgtvIdRxkzQRva1IE6ElAp5hzAvvOpUQek5BbWZKQxyTkKYnCufp76Tvjj_UFcHsCQDl9cJBk1g6CLv4k0L000f1H_jcUUpy_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Dillon, Kearsley M. ; Carrazzone, Ryan J. ; Matson, John B. ; Kashfi, Khosrow</creator><creatorcontrib>Dillon, Kearsley M. ; Carrazzone, Ryan J. ; Matson, John B. ; Kashfi, Khosrow</creatorcontrib><description>[Display omitted]
Nitric oxide (NO) and hydrogen sulfide (H2S) are industrial toxins or pollutants; however, both are produced endogenously and have important biological roles in most mammalian tissues. The recognition that these gasotransmitters have a role in physiological and pathophysiological processes has presented opportunities to harness their intracellular effects either through inhibition of their production; or more commonly, through inducing their levels and or delivering them by various modalities. In this review article, we have focused on an array of NO and H2S donors, their hybrids with other established classes of drugs, and the various engineered delivery platforms such a fibers, polymers, nanoparticles, hydrogels, and others. In each case, we have reviewed the rationale for their development.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/j.bcp.2020.113931</identifier><identifier>PMID: 32224139</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Animals ; Cystathionine beta-Synthase - metabolism ; Cystathionine gamma-Lyase - metabolism ; Cysteine - metabolism ; Delivery platforms ; Fibers ; Gasotransmitters - metabolism ; H2S-releasing hybrids ; Humans ; Hydrogels ; Hydrogen sulfide ; Hydrogen Sulfide - metabolism ; Nanoparticles ; Nitric oxide ; Nitric Oxide - metabolism ; Nitric Oxide Synthase - metabolism ; NO-releasing compounds ; Polymers ; Signal Transduction</subject><ispartof>Biochemical pharmacology, 2020-06, Vol.176, p.113931-113931, Article 113931</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-6ff1b330e9e1220fb8b440ec71e8b71bd4a26ad7ef3930698de68505d6d607633</citedby><cites>FETCH-LOGICAL-c451t-6ff1b330e9e1220fb8b440ec71e8b71bd4a26ad7ef3930698de68505d6d607633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006295220301593$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32224139$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dillon, Kearsley M.</creatorcontrib><creatorcontrib>Carrazzone, Ryan J.</creatorcontrib><creatorcontrib>Matson, John B.</creatorcontrib><creatorcontrib>Kashfi, Khosrow</creatorcontrib><title>The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>[Display omitted]
Nitric oxide (NO) and hydrogen sulfide (H2S) are industrial toxins or pollutants; however, both are produced endogenously and have important biological roles in most mammalian tissues. The recognition that these gasotransmitters have a role in physiological and pathophysiological processes has presented opportunities to harness their intracellular effects either through inhibition of their production; or more commonly, through inducing their levels and or delivering them by various modalities. In this review article, we have focused on an array of NO and H2S donors, their hybrids with other established classes of drugs, and the various engineered delivery platforms such a fibers, polymers, nanoparticles, hydrogels, and others. In each case, we have reviewed the rationale for their development.</description><subject>Animals</subject><subject>Cystathionine beta-Synthase - metabolism</subject><subject>Cystathionine gamma-Lyase - metabolism</subject><subject>Cysteine - metabolism</subject><subject>Delivery platforms</subject><subject>Fibers</subject><subject>Gasotransmitters - metabolism</subject><subject>H2S-releasing hybrids</subject><subject>Humans</subject><subject>Hydrogels</subject><subject>Hydrogen sulfide</subject><subject>Hydrogen Sulfide - metabolism</subject><subject>Nanoparticles</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>NO-releasing compounds</subject><subject>Polymers</subject><subject>Signal Transduction</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UV1rGzEQFCWlcdz8gL4E_QE7-jjr7hIIGNOmhUBf0mehk1a2jCwZ6XzJJX--Mk5D-9InaXdnZtkZhL5QMqeEiuvtvNP7OSOs1JS3nH5AE9rUfMZa0ZyhCSFElP-CnaOLnLfHshH0EzrnjLGqMCbo9XEDGIboBxfW2KtgslZ7wDYmrMH7g1cJB9cnp3F8dgZwgeDNaFJcQ8D54O2xacC7AdKI85h72OUbvMQBnjAkhaPF-pD7uHMvYPAOjNOqdzHkz-ijVT7D5ds7Rb--fX1cfZ89_Lz_sVo-zHS1oP1MWEs7zgm0QBkjtmu6qiKgawpNV9POVIoJZWqwxQIi2saAaBZkYYQRpBacT9HdSXd_6Mp6DaFPyst9cjuVRhmVk_9OgtvIdRxkzQRva1IE6ElAp5hzAvvOpUQek5BbWZKQxyTkKYnCufp76Tvjj_UFcHsCQDl9cJBk1g6CLv4k0L000f1H_jcUUpy_</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Dillon, Kearsley M.</creator><creator>Carrazzone, Ryan J.</creator><creator>Matson, John B.</creator><creator>Kashfi, Khosrow</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20200601</creationdate><title>The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications</title><author>Dillon, Kearsley M. ; Carrazzone, Ryan J. ; Matson, John B. ; Kashfi, Khosrow</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-6ff1b330e9e1220fb8b440ec71e8b71bd4a26ad7ef3930698de68505d6d607633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Cystathionine beta-Synthase - metabolism</topic><topic>Cystathionine gamma-Lyase - metabolism</topic><topic>Cysteine - metabolism</topic><topic>Delivery platforms</topic><topic>Fibers</topic><topic>Gasotransmitters - metabolism</topic><topic>H2S-releasing hybrids</topic><topic>Humans</topic><topic>Hydrogels</topic><topic>Hydrogen sulfide</topic><topic>Hydrogen Sulfide - metabolism</topic><topic>Nanoparticles</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>NO-releasing compounds</topic><topic>Polymers</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dillon, Kearsley M.</creatorcontrib><creatorcontrib>Carrazzone, Ryan J.</creatorcontrib><creatorcontrib>Matson, John B.</creatorcontrib><creatorcontrib>Kashfi, Khosrow</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dillon, Kearsley M.</au><au>Carrazzone, Ryan J.</au><au>Matson, John B.</au><au>Kashfi, Khosrow</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>176</volume><spage>113931</spage><epage>113931</epage><pages>113931-113931</pages><artnum>113931</artnum><issn>0006-2952</issn><eissn>1873-2968</eissn><abstract>[Display omitted]
Nitric oxide (NO) and hydrogen sulfide (H2S) are industrial toxins or pollutants; however, both are produced endogenously and have important biological roles in most mammalian tissues. The recognition that these gasotransmitters have a role in physiological and pathophysiological processes has presented opportunities to harness their intracellular effects either through inhibition of their production; or more commonly, through inducing their levels and or delivering them by various modalities. In this review article, we have focused on an array of NO and H2S donors, their hybrids with other established classes of drugs, and the various engineered delivery platforms such a fibers, polymers, nanoparticles, hydrogels, and others. In each case, we have reviewed the rationale for their development.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>32224139</pmid><doi>10.1016/j.bcp.2020.113931</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-2952 |
| ispartof | Biochemical pharmacology, 2020-06, Vol.176, p.113931-113931, Article 113931 |
| issn | 0006-2952 1873-2968 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7263970 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Cystathionine beta-Synthase - metabolism Cystathionine gamma-Lyase - metabolism Cysteine - metabolism Delivery platforms Fibers Gasotransmitters - metabolism H2S-releasing hybrids Humans Hydrogels Hydrogen sulfide Hydrogen Sulfide - metabolism Nanoparticles Nitric oxide Nitric Oxide - metabolism Nitric Oxide Synthase - metabolism NO-releasing compounds Polymers Signal Transduction |
| title | The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A30%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20evolving%20landscape%20for%20cellular%20nitric%20oxide%20and%20hydrogen%20sulfide%20delivery%20systems:%20A%20new%20era%20of%20customized%20medications&rft.jtitle=Biochemical%20pharmacology&rft.au=Dillon,%20Kearsley%20M.&rft.date=2020-06-01&rft.volume=176&rft.spage=113931&rft.epage=113931&rft.pages=113931-113931&rft.artnum=113931&rft.issn=0006-2952&rft.eissn=1873-2968&rft_id=info:doi/10.1016/j.bcp.2020.113931&rft_dat=%3Celsevier_pubme%3ES0006295220301593%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32224139&rft_els_id=S0006295220301593&rfr_iscdi=true |